CUREVAC N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.13 USD | +13.00% |
|
+34.33% | -25.65% |
| May. 02 | CUREVAC : A missed opportunity |  |
| Apr. 26 | UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating | MT |
Presentation Operator MessageOperator (Operator)Greetings, and welcome to the CureVac Fourth Q...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve peopleâs lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
Calendar
2024-05-21
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
2.906
EUR
Average target price
9.189
EUR
Spread / Average Target
+216.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -25.65% | 701M | |
| +25.69% | 47.86B | |
| +46.90% | 41.42B | |
| -3.46% | 40.66B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +28.07% | 12.14B | |
| +0.17% | 12.15B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- CVAC Stock
- News CureVac N.V.
- Transcript : CureVac N.V., Q4 2023 Earnings Call, Apr 24, 2024
